Джейн Плант - Антирак груди
310
www.ahrq.gov/news/press/pr2002/brchempr.htm
311
www.ahrq.gov/news/press/pr2002/brchempr.htm
312
http://cis.nci.nih.gov/fact/7_16.htm
313
Gottlieb, Scott, 2002. Tamoxifen may increase risk of uterine sarcoma, BMJ, 325, 7.
314
http://cis.nci.nih.gov/fact/7_16.htm
315
Mayor, Susan, 2002. Anastrozole shows promise for early breast cancer. BMJ, 324, 1539
316
www.gene.com/gene/products/information/oncology/herceptin; www.herceptin.com/herceptin/physician/pi.htm
317
http://cis.nci.nih.gov/fact/7_45.htm
318
New Scientist, 20 January, 2007.
319
Editorial, New Scientist, 31 March, 2007.
320
Josefson, Deborah, 2002. Doctors warned to be wary of new drugs. BMJ, 324, 1113.
321
Garattini, Silvio and Bertele, Vittorio, 2002. Efficacy, safety, and cost of new anticancer drugs. BMJ, 325, 269–271.
322
www.cancer.gov
323
Modified after: Chemotherapy and You: A Guide to Self-Help During Cancer Treatment. Information about what to expect during chemotherapy and what patients can do to take care of themselves during and after treatment NIH Publication #99–1136: www.cancer.gov/cancerinfo/chemorherapy-and-you
324
Smith, I. and Chue, S., 2006. Medical treatment of early breast cancer. BMJ, 332, 162–181.
325
Allison, R. and others, 2006. Photodiagnosis and photodynamic therapy, 3, 139–146.
326
Fritsch, C. and Ruzika, T., 2003. Fluorescence diagnosis and photodynamic therapy of skin diseases atlas and handbook. Vien: Springer-Verlag.
327
Абляция (лат. ablatio – отнятие) – специфическое хирургическое вмешательство; абляция подразумевает под собой выжигание или выпаривание дисфункциональной или патологически измененной ткани с использованием лазера, радиочастотного аппарата, тока или химии; также данная операция может проводиться классическим хирургическим вмешательством. – Примеч. ред.
328
Coulter; Angela, 2003. Killing the goose that laid the golden egg. BMJ, 326, 1280.
329
Coulter, Angela, 2003. Killing the goose that laid the golden egg. BMJ, 326, 1280.
330
Ernst, E., 2003. Herbal medicines put into context. BMJ, 327, 881–882.
331
Waxman, Jonathan, 2001. The Prostate Cancer Book. London: Vermillion.
332
Dyer, Owen, 2003. Aspirin could be used to prevent cancer. BMJ, 326, 565.
333
Flower, Rod, 2003. What are all the things that aspirin does? BMJ, 327, 572–573.
334
UK limits use of aspirin by under 16s. BMJ, 2002, 324, 1294.
335
Astralagus. ICON, 2002, 1 (3), 23.
336
Bartram, T., 1998. Bartram's encyclopedia of herbal medicine. Robinson publishing.
337
Campbell, T. C. and Campbell, T. M., 2006. The China Study. Benbella Books.
338
Рейки – вид комплементарной медицины, в котором используется техника так называемого исцеления путем наложения рук. – Примеч. ред.
339
Greenwald, Peter, 2002. Cancer chemoprevention. BMJ, 324, 714–718.
340
Clarke, M.F. and Becker, M.W., 2006. Stem cells: the real culprits in cancer? Scientific American, July 2006, 53–59.
341
Study reveals how growth factors affect human stem cells. www.hhmi.org/news/melton.hmtl
342
Murray, R.K., Granner, D.K., Mayes, P.A. and Rodwell, V.W., 1990. Harper's Biochemistry. Appleton and Lange Norwalk, CT, p. 653.
343
Woolf, Neville, 1998. Pathology, Basic and Systemic. W.B. Saunders Publishing Co., Chapter 28, p. 274, Figure 28.
344
www.intouchlive.com/cancergenetics/onco.htm
345
Ludwig, T., Fisher, P., Ganesan, S. and Efstratiadis, 2001. Tumorigenesis in mice carrying a truncating BRCA1 mutation. Genes and Development, Vol. 15 (10), 1188–1193.
346
Xu, X., Wagner, K.U., Larson, D., Weaver, Z., Li, C., Ried, T., Hennighausen, L., Wynshaw-Boris, A. and Deng, C.X. 1999. Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics, Vol. 22 (1), 37–43.
347
Paull, T.T, Cortez, D., Bowers, B., Elledge, S.J. and Gellert, M., 2001. Direct DNA binding by BRCA1. Proceedings of the National Academy of Sciences of the USA , Vol. 98 (11), 6086–6091.
348
Jensen, R.A., Thompson, M.E., Jetton, T.L., Szabo, C.I., van der Meer, R., Helou, B., Tronick, S., King, M.C., Page, D.L. and Holt, J.T., 1996. BRCA1 is secreted and exhibits properties of a granin. Nature Genetics, 12, 303–308; www.mc.vanderbilt.edu/cancer/research/roster/jensen.html
349
Struewing, J.P., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M.M., Collins, F.S. and Brody, L.C., 1995. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi-Jewish individuals. Nature Genetics, 11, 198–200; http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html
350
Roa, B.B., Boyd, A.A., Volcik, K. and Richards, C.S., 1996. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14, 185–187; Oddoux, C., Struewing, J.P., Clayton, C.M., Neuhausen, S., Vrody, L.C., Kaback, M., Haas, B., Norton, L., Borgen, P. Jhanwar, S., Golgar, D., Ostrer, H. and Offit, K., 1996. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %. Nature Genetics, 14, 188–190; http://rex.nci.nih.gov/massmedia/backgrounders/ashkenazi.html
351
www.mercola.com/2002/apr/27/sv40.htm
352
Hursting, S.D., Slaga,T.J., Fischer, S.M., DiGiovanni, J. and Phtans, J. M., 1999. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. Journal of the National Cancer Institute, 35, 2031–2038.
353
Cheeseman, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.
354
Cheeseman, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.
355
Stewart, H.J., 1989. Clinical experience in the use of antioestrogen tamoxifen in the treatment of breast cancer. Proceedings of the Royal Society of Edinburgh , 95B, 231–237.
356
Miller, W. R., 1997. Aromatase inhibitors and breast cancer. Cancer Treatment Reviews, 23, 113–131.
357
Dao, T.L., Sinha, D.K., Nemato, T. and Patel, J., 1982. Effects of estrogens and progesterone on cellular replication of human breast tumours. Cancer Research, 42, 359–362.
358
Conte, P.P., Fraschini, G. and Dewinko, B., 1985. Estrogen induced expansion of the growth fraction in receptor negative human breast cancer. Journal of Steroid Biochemistry, 23, 1169–1172.
359
Miller, W.R. and Langdon, S.P., 1997. Hormonal, growth factor and cytokine control of breast cancer. In: Biology of Female Cancers, pp. 43–60. Langdon, S,P., Miller, W.R. and Berchuck, A. (editors). New York: CRC Press.
360
(adsbygoogle = window.adsbygoogle || []).push({});
